Application of Lipofermata in preparation of medicine for preventing and / or treating coronavirus infection

By using Lipofermata as a fatty acid transporter 2 inhibitor and combining with pharmaceutical carriers to make a pharmaceutical composition, the problem of lack of universality and drug targeting of coronavirus treatment methods in the prior art is solved, and effective inhibition of coronavirus and Safe and high therapeutic effect.

CN118903121APending Publication Date: 2024-11-08SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411264559.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing coronavirus treatment methods lack universality, and different coronaviruses have different biological characteristics and high variability rates, which affect the targeting and therapeutic effects of drugs, leading to the development of broader and more effective anti-coronavirus drugs. Become an urgent need.

Method used

Lipofermata is used as a fatty acid transporter 2 (FATP2) inhibitor, and its inhibitory effect on multiple cell models is identified and verified by high-throughput screening methods, and combined with pharmaceutically acceptable carriers to prepare pharmaceutical compositions for the preparation of prevention and /or drugs to treat coronavirus infection, including solid, semi-solid and liquid preparations, significantly inhibit the replication of coronavirus in cells.

Benefits of technology

Lipofermata shows obvious inhibitory effects on SARS-CoV-2 and MHV-A59 viruses, which have low toxicity and high safety, can be used to prevent and treat coronavirus infections, and has no significant impact on normal cell growth, providing a A broad spectrum of anti-coronavirus drug solutions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903121A_ABST
    Figure CN118903121A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to application of Lipoferra in preparation of a medicine for preventing and treating coronavirus infection, and the structure of Lipoferra is as shown in formula (I). According to the application, research finds that Lipoferra has a remarkable effect of resisting coronavirus replication, and the Lipoferra is high in safety within the dosage of a therapeutically effective dose of medicine, so that the Lipoferra has a relatively high clinical application value. # imgabs0 # formula (I)
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine technology, and specifically to the use of Lipofermata in the preparation of a drug for preventing and / or treating coronavirus infection. Lipofermata is a compound represented by formula (I). Background Art

[0002] Coronaviruses are a class of viruses with an envelope and a linear single-stranded positive-sense RNA genome. They are widely found in nature and can infect a variety of vertebrates, including humans, causing respiratory, digestive and nervous system diseases. According to the phylogenetic tree, coronaviruses can be divided into four genera: α, β, γ and δ. Among them, the β-genus coronavirus can be divided into four subgroups: A, B, C and D. Studies have found that coronaviruses that are easily infected with humans mainly belong to the β-genus, such as SARS-CoV, MERS-CoV and SARS-CoV-2, which are usually highly contagious and widely spread.

[0003] The clinical manifestations of coronavirus infection vary from the common cold to severe respiratory diseases. For example, SARS-CoV and MERS-CoV usually cause more severe symptoms, including high fever, persistent cough and shortness of breath, which can develop into respiratory distress syndrome in severe cases, while HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 usually cause mild symptoms similar to the common cold. In short, coronavirus is a class of viruses with important public health significance, which requires continuous attention and research on corresponding prevention, control and treatment strategies to protect human health and safety.

[0004] At present, the methods for treating coronavirus include drug therapy, supportive therapy, oxygen therapy, mechanical ventilation, etc. The specific treatment plan needs to be formulated according to the type of coronavirus, the severity of the patient's condition and individual differences. Clinically, no universal drug with good efficacy against coronavirus has been found. This is mainly because different coronaviruses have different biological characteristics, infection mechanisms and drug sensitivity. In addition, coronaviruses also have a high mutation rate, which may affect the targeting and therapeutic effect of the drug. Developing a broader-spectrum and more effective anti-coronavirus drug has become one of the current focuses of developing anti-coronavirus drugs.

[0005] Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor identified by high-throughput screening methods. Its inhibitory effect on fatty acid transport has been verified in a variety of cell models, including cardiomyocytes, pancreatic β cells, intestinal epithelial cells and hepatocytes. It also has antibacterial, anti-tumor, anti-renal fibrosis and anti-osteoporosis effects, and is a compound with important research value. Summary of the invention

[0006] The present application has conducted extensive research and extensive study on Lipofermata and found that Lipofermata can be used to prevent and / or treat coronavirus infection.

[0007] Based on this, the following technical solutions are proposed:

[0008] Use of a compound represented by formula (I) in the preparation of a drug for preventing and / or treating coronavirus infection;

[0009] Formula (I).

[0010] Furthermore, the coronavirus is selected from beta coronavirus.

[0011] Furthermore, the coronavirus includes at least one of SARS-CoV, MERS-CoV, SARS-CoV-2 and MHV-A59.

[0012] Use of a pharmaceutical composition in the preparation of a drug for preventing and / or treating coronavirus infection, the pharmaceutical composition comprising an active ingredient and a pharmaceutically acceptable carrier;

[0013] The active ingredient includes a compound represented by formula (I);

[0014] Formula (I).

[0015] Furthermore, the coronavirus is selected from beta coronavirus.

[0016] Furthermore, the coronavirus includes at least one of SARS-CoV, MERS-CoV, SARS-CoV-2 and MHV-A59.

[0017] Furthermore, the pharmaceutical composition and pharmaceutically acceptable excipients are prepared together into a preparation.

[0018] Furthermore, the dosage form of the preparation includes solid preparation, semi-solid preparation and liquid preparation.

[0019] Furthermore, the compound represented by formula (I) is the only active ingredient in the pharmaceutical composition.

[0020] Furthermore, the prevention and / or treatment of coronavirus infection includes inhibiting the replication of the coronavirus in cells.

[0021] The research in this application found that the compound Lipofermata shown in formula (I) has a significant effect on anti-coronavirus replication, and has no obvious effect on the growth and proliferation of normal cells, with low toxicity and high safety; experiments have shown that the compound has a significant inhibitory effect on SARS-CoV-2 and MHV-A59 viruses, and can be used to prepare drugs for preventing and / or treating coronavirus infections. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0023] Figure 1 This is a comparison chart of the inhibitory effects of the experimental group and the blank group on SARS-CoV-2 replicons in one embodiment of the present application; Figure 1 The horizontal axis 1.25 μM represents the experimental group with a Lipofermata concentration of 1.25 μM, DMSO represents the blank group, and the vertical axis is the logarithm of the fluorescence intensity (Log 10 );

[0024] Figure 2 This is a comparison chart of the inhibitory effects of the Lipofermata group and the DMSO group on the MHV-A59-ZsGreen live virus in one embodiment of the present application; Figure 2 The horizontal axis 1.25 μM represents the experimental group with a Lipofermata concentration of 1.25 μM, DMSO represents the blank group, and the vertical axis is the logarithm of the virus inhibition titer (Log 10 pfu / mL);

[0025] Figure 3 This is a comparison diagram of the cytotoxic effects of Lipofermata on Huh7, 17CL-1 and L2 cells in an embodiment of the present application; Figure 3 The horizontal axis is the logarithm of Lipofermata concentration (Log 10 μM), the ordinate is the cell survival rate (%);

[0026] Figure 4 This is a comparison chart of the inhibitory effects of different concentrations of Lipofermata on SARS-CoV-2 virus replicons in Huh7 cells in an embodiment of the present application; Figure 4The horizontal axis 0.5μM, 1μM, 1.5μM and 2μM represent the experimental groups with lipofermata concentrations of 0.5μM, 1μM, 1.5μM and 2μM, respectively. DMSO represents the blank group. The vertical axis is the logarithm of the fluorescence intensity (Log 10 );

[0027] Figure 5 This is a comparison diagram of the inhibitory effects of different concentrations of Lipofermata on MHV-A59-ZsGreen live virus in 17CL-1 and L2 cells in an example of the present application; Figure 5 The horizontal axis 0.5μM, 1μM, 1.25μM, 1.5μM, 2μM and 4μM represent the experimental groups with lipofermata concentrations of 0.5μM, 1μM, 1.25μM, 1.5μM, 2μM and 4μM, respectively. DMSO represents the blank group. The vertical axis is the logarithm of the virus inhibition titer (Log 10 pfu / mL). DETAILED DESCRIPTION

[0028] The present application will be further described below in conjunction with the embodiments and examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. In addition, it should be understood that after reading the content taught in the present application, those skilled in the art may make various changes or modifications to the present application, and these equivalent forms also fall within the protection scope of the claims attached to the present application.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0030] the term

[0031] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0032] The term "and / or" used in this article includes any one of two or more related listed items, and also includes any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0033] In the present application, "further" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.

[0034] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0035] In this application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.

[0036] In the present application, weight may be μg, mg, g, kg or other mass units known in the chemical industry.

[0037] Unless otherwise specified, percentage contents in this application refer to mass percentage for solid-liquid mixing and solid-solid mixing, and volume percentage for liquid-liquid mixing.

[0038] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0039] The temperature parameters in this application, unless otherwise specified, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range of instrument control.

[0040] As used herein, "drug" includes any agent, compound, composition or mixture that provides physiological and / or pharmacological effects in vivo or in vitro, and often provides beneficial effects. The scope of the physiological and / or pharmacological effects produced by the "drug" in vivo is not particularly limited, and may be systemic effects or may only produce effects locally. The activity of the "drug" is not particularly limited, and may be an active substance that can interact with other substances, or may be an inert substance that does not interact.

[0041] Herein, a "composition" may be a combination of multiple substances, and further, may be used in combination, or may be a mixture of the combination.

[0042] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0043] As used herein, "pharmaceutically acceptable carriers" include buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, which are compatible with drug administration. Each substance must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, and taffeta. Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffered saline; and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0044] Herein, "subject" and "patient" refer to animals, preferably mammals, more preferably humans, and subjects include but are not limited to patients with diseases, disorders and / or symptoms. The term "mammal" mainly refers to warm-blooded vertebrate mammals, including but not limited to: such as cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats, mice), pigs, cattle, sheep, horses, humans, etc., preferably primates, more preferably humans.

[0045] One embodiment of the present application provides a use of a compound represented by formula (I) in the preparation of a drug for preventing and / or treating coronavirus infection;

[0046] Formula (I).

[0047] In some embodiments, the coronavirus is selected from a beta coronavirus.

[0048] In some embodiments, the coronavirus includes at least one of SARS-CoV, MERS-CoV, SARS-CoV-2, and MHV-A59.

[0049] An embodiment of the present application provides a use of a pharmaceutical composition in the preparation of a drug for preventing and / or treating coronavirus infection, the pharmaceutical composition comprising an active ingredient and a pharmaceutically acceptable carrier;

[0050] The active ingredient includes a compound represented by formula (I);

[0051] Formula (I).

[0052] See above for the definition of coronavirus.

[0053] In some embodiments, the pharmaceutical composition and pharmaceutically acceptable excipients are prepared together as a preparation. Herein, pharmaceutically acceptable excipients include, but are not limited to, diluents, wetting agents, adhesives, disintegrants, lubricants, color and flavor regulators, solvents, solubilizers, cosolvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH regulators, isotonic or isotonic regulators, etc. Further: diluents, such as starch, sucrose, cellulose, inorganic salts, etc.; wetting agents, such as water, ethanol, etc.; adhesives, such as starch slurry, dextrin, sugar, cellulose derivatives, gelatin, povidone, polyethylene glycol, etc.; disintegrants, such as starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, sodium cross-linked methyl cellulose, cross-linked polyvidone, surfactants, runteng disintegrants, etc.; lubricants, such as talc, calcium stearate, magnesium stearate, magnesium lauryl sulfate, micro-powder silica gel, polyethylene glycol, etc.; color and flavor regulators, such as pigments, flavors, sweeteners, Flavoring agents, adhesives, deodorants, etc., such as fuchsin and xylitol; solvents, such as water, oil, ethanol, glycerol, propylene glycol, polyethylene glycol, dimethyl sulfoxide, liquid paraffin, fatty oil, ethyl acetate, etc.; solubilizers, such as Tweens, sorbents, polyoxyethylene fatty alcohol ethers, soaps, sulfates, sulfonates, etc.; cosolvents, such as organic acids (such as citric acid) and their salts, amide and amine compounds, inorganic salts, polyethylene glycol, povidone, glycerol, etc.; emulsifiers, such as spans, tweens, sorbents, benzyls, glycerol fatty acid esters, high fatty acid salts, sulfates, sulfonates, gum arabic, tragacanth gum, gelatin, pectin, phospholipids, agar, sodium alginate, hydroxides, silicon dioxide, bentonite, etc.; suspending agents, such as glycerol, syrup, gum arabic, tragacanth gum, agar, sodium alginate, cellulose derivatives, povidone, carbopol, polyvinyl alcohol, thixotropic glue, etc.; antioxidants, such as sulfites, pyrosulfites, bisulfites, ascorbic acid, gallic acid and its esters, etc.; metal complexing agents, such as disodium ethylenediaminetetraacetic acid, polycarboxylic acid compounds, etc.; inert gases, such as Nitrogen, carbon dioxide, etc.; preservatives, such as parabens, organic acids and their salts (such as sodium benzoate), quaternary ammonium compounds, chlorhexidine acetate, alcohols, phenols and volatile oils, etc.; local analgesics, such as benzyl alcohol, chlorobutanol, lidocaine and procaine, etc.; pH adjusters, such as hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, acetic acid, sodium hydroxide, sodium bicarbonate, ethylenediamine, meglumine, phosphates, acetates, citric acid, citrate, etc.; isotonic or isotonic adjusters, such as glucose, sodium chloride, sodium citrate, sorbitol and xylitol, etc.It can be understood that the diluent described in the embodiments of the present application can also be called a filler, which plays the same role in the pharmaceutical preparation; the water described in the embodiments of the present application is water that meets the requirements of the medicine, such as water for injection, purified water, etc., and the oil is oil for injection; the preservative described in the embodiments of the present application can also be called an antibacterial agent, which plays a role in inhibiting the growth of microorganisms and prolonging the shelf life in the preparation; the lubricant described in the embodiments of the present application contains a flow aid, an anti-adhesive agent, etc.; the sugar described in the embodiments of the present application can be powdered sugar or syrup, and the type of sugar is not limited to glucose; the flavors described in the embodiments of the present application include but are not limited to flavors.

[0054] In some embodiments, the dosage form of the preparation includes solid preparations, semi-solid preparations and liquid preparations.

[0055] In some embodiments, the compound represented by formula (I) is the only active ingredient in the pharmaceutical composition.

[0056] In some embodiments, the pharmaceutical composition comprises: (a) a compound represented by formula (I); and (b) an excipient and / or a carrier.

[0057] In some embodiments, the pharmaceutical composition comprises a compound represented by formula (I) and a carrier, and further, the carrier is DMSO; further, the concentration of the compound represented by formula (I) in the pharmaceutical composition is selected from 0.5 μM to 5 μM, for example 0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, etc.

[0058] In some embodiments, preventing and / or treating coronavirus infection comprises inhibiting the replication of coronavirus in cells.

[0059] The pharmaceutical composition of the present application contains an effective amount of a compound represented by formula (I). Herein, "effective amount" refers to the dosage of the component corresponding to the term to achieve treatment, prevention, alleviation and / or relief of a specific disease, condition and / or symptom in a subject. Herein, unless otherwise specified, it refers to the dosage to achieve treatment, prevention, alleviation and / or relief of symptoms of coronavirus infection. Herein, the subject may be a mammal. Further, the subject is a mouse or a human.

[0060] According to the above application, the present application also provides a method for preventing or treating coronavirus infection, comprising administering a therapeutically effective amount of a compound shown in formula (I) to a patient in need. That is, administering a therapeutically effective amount of a compound shown in formula (I) to a patient. Herein, "patient" refers to an animal, preferably a mammal, and more preferably a human. The term "mammal" mainly refers to warm-blooded vertebrate mammals, including but not limited to: such as cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice, pigs, cattle, sheep, horses, humans, etc., preferably primates, and more preferably humans.

[0061] Directions of administration:

[0062] The dosage form and administration method of the compound represented by formula (I) (Lipofermata) or its pharmaceutical composition of the present application are not particularly limited.

[0063] Representative routes of administration include, but are not limited to, oral, rectal, parenteral (intravenous, intramuscular or subcutaneous) injection, and topical administration.

[0064] Solid dosage forms for oral administration include tablets, capsules, granules, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may also contain a buffer. Solid dosage forms such as tablets, sugar pills, capsules, pills and granules may be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions may be delayed in a certain part of the digestive tract. Examples of embedding components that may be used are polymeric substances and waxes. If necessary, the active compound may also be formed into microcapsules with one or more of the above-mentioned excipients.

[0065] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, specifically, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances. In addition to these inert diluents, the composition may also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and spices. For example, the suspension may contain a suspending agent, specifically, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methylate and agar or mixtures of these substances.

[0066] Compositions for rectal and parenteral injections may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous or non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0067] Dosage forms for topical administration include ointments, powders, patches, sprays and inhalants, which are prepared by mixing the active ingredient with a pharmaceutically acceptable carrier and any preservatives, buffers, or propellants that may be required under sterile conditions.

[0068] The following are some specific embodiments.

[0069] For experimental parameters not specified in the following specific embodiments, reference is made to the instructions given in the present application document, and reference may also be made to experimental manuals in the art or other experimental methods known in the art, or to experimental conditions recommended by manufacturers.

[0070] The raw materials and reagents involved in the following specific examples can be obtained from commercial sources, or can be prepared by those skilled in the art according to known methods.

[0071] The sources of some cells and virus samples used in the following examples are shown in Table 1.

[0072] Table 1

[0073]

[0074] Example 1

[0075] This example shows the research process and results of the inhibitory effect of Lipofermata on SARS-CoV-2 replicon and MHV-A59-ZsGreen live virus.

[0076] 1. Study on the inhibitory effect of Lipofermata on SARS-CoV-2 replicon

[0077] 1.1 Experimental methods for SARS-CoV-2 virus replicon

[0078] 1.1.1 Take Huh7 cells at 4×10 4 The cells were seeded at a density of 100 μL / mL in a 48-well plate, with 210 μL per well. The cells were cultured in a 37°C, 5% CO2 incubator using 10% FBS DMEM medium (plus 1% double antibody).

[0079] 1.1.2 After 24 h of culture, the cells entered the exponential phase of growth. The DMEM medium was discarded and 10% FBS DMEM medium containing DMSO and 1.25 μM Lipofermata (prepared with DMSO) was added as the blank control group and experimental group, respectively, and cultured in a 37°C, 5% CO2 incubator for 1 h.

[0080] 1.1.3 Prepare SARS-CoV-2 virus replicon RNA transfection system: Add 100 ng of SARS-CoV-2 virus replicon RNA and 0.5 μL of transfection reagent Lipfectamine ®2000 to 50 μL of opti-MEM® I medium and incubate for 15 min. Add 100 μL of transfection system to each well in step 2.

[0081] 1.1.4 24 hours after transfection of replicon RNA, cells were collected and the fluorescence value of each well was detected using Nano glo® (purchased from Promega) kit and 96-well microwell luminescence detector. The fluorescence value reflects the activity of NanoLuc® luciferase, and the enzyme activity reflects the replication level of the replicon.

[0082] 1.1.5 Experimental results: Figure 1 As shown, 24 hours after replicon transfection, the replicon replication level in the experimental group decreased by about 13 times compared with the blank control group, indicating that Lipofermat significantly inhibited the replication of SARS-CoV-2.

[0083] 2. Study on the inhibitory effect of Lipofermata on MHV-A59-ZsGreen live virus

[0084] MHV-A59 is a specific strain of Mouse Hepatitis Virus (MHV), belonging to the Coronaviridae family, and is widely used to study the replication mechanism and pathogenicity of coronaviruses and as a model virus for antiviral drug screening. MHV-A59-ZsGreen is a derivative version of MHV-A59, in which the ZsGreen reporter gene is inserted into its genome, a green fluorescent protein that enables researchers to visually observe virus-infected cells through a fluorescent microscope, making it easier to study the replication characteristics of the virus and conduct drug screening.

[0085] 2.1 Experimental methods for MHV-A59-ZsGreen live virus

[0086] 2.1.1 17CL-1 cells were cultured at 3×10 5 The number of L2 cells / mL and 6×10 5The cells were seeded at a density of 100 cells / mL in a 12-well plate, 1 mL per well, and cultured in a 37°C, 5% CO2 incubator using 10% FBS DMEM medium.

[0087] 2.1.2 After 24 h of culture, the cells entered the exponential growth phase and the culture medium was discarded. 10% FBS DMEM culture medium containing DMSO and 1.25 μM Lipofermata was added to L2 and 17CL-1 cells as blank control group and experimental group, respectively, and cultured in an incubator at 37°C and 5% CO2 for 1 h.

[0088] 2.1.3 Discard the culture medium in each well and add 1 mL of 10% FBS DMEM culture medium and 10 μL of MHV-A59-ZsGreen live virus solution. Place the culture plate in a 37°C, 5% CO2 incubator. After culturing for 1 hour, discard the virus-containing culture medium and add 10% FBS DMEM culture medium containing DMSO or 1.25μM Lipofermata, respectively, and place in a 37°C, 5% CO2 incubator for 24 hours.

[0089] 2.1.4 Experimental results: Figure 2 As shown, in 17CL-1 and L2 cells, the virus titer of the experimental group was significantly decreased compared with the blank control group, indicating that Lipofermata has a significant inhibitory effect on MHV virus and has a high efficacy.

[0090] Example 2

[0091] This example is a cytotoxicity experiment of Lipofermata on Huh7, 17CL-1 and L2 cells.

[0092] 1. Experimental Methods

[0093] 1.1 Huh7 and 17CL-1 cells were cultured at 2×10 4 The density of L2 cells was 4×10 4 The cells were inoculated in 96-well plates at a density of 100 μL per well, and cultured in a 37°C, 5% CO2 incubator with 10% FBS DMEM medium.

[0094] 1.2 After 24 h of culture, the cell growth entered the exponential phase, and the concentration gradient group of Lipofermata was prepared, starting from 100 μM and diluted 10 times in two-fold ratio (i.e., the concentrations were 100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.12 μM, 1.56 μM, 0.78 μM, 0.39 μM, 0.195 μM and 0.098 μM), with a total of 11 concentration gradients. The drugs of each concentration were added to the cell culture wells, and 3 replicate wells were set for each concentration.

[0095] 1.3 After the cells were placed in an incubator at 37°C and 5% CO2 for 24 h, 10 μL of cholecystokinin octapeptide (CCK8) substrate solution was added to each well;

[0096] 1.4 After the cells were cultured for 1 h, the absorbance of each well was measured at 450 nm using an enzyme-linked immunosorbent assay.

[0097] 1.5 The CC50 curves of Lipofermata in Huh7, 17CL-1 and L2 cells were fitted using GraphPad Prism 8.0 software.

[0098] 2. Experimental Results

[0099] like Figure 3 As shown, the CC50 of Lipofermata in Huh7, 17CL-1 and L2 cells were 213.1 μM, 33.91 μM and 62.21 μM, respectively, indicating that Lipofermata has a high safety profile.

[0100] Example 3

[0101] This example shows the inhibitory effect of different concentrations of Lipofermata on the novel coronavirus replicon in Huh7 cells; and the inhibitory effect of different concentrations of Lipofermata on the MHV-A59-ZsGreen live virus in 17CL-1 and L2 cells.

[0102] 1. Inhibitory effect of different concentrations of Lipofermata on SARS-CoV-2 virus replicon in Huh7 cells

[0103] 1.1 Take Huh7 cells at 4.2×10 4 The cells were seeded at a density of 100 μL / mL in a 48-well plate, with 210 μL per well. The cells were cultured in a 37°C, 5% CO2 incubator using 10% FBS DMEM medium (plus 1% double antibody).

[0104] 1.2 After 24 h of culture, cell growth entered the exponential phase. Lipofermata concentration gradient groups were prepared, with 4 concentration gradients set up, namely 0.5 μM, 1 μM, 1.5 μM and 2 μM. Each concentration of drug was added to the cell culture wells, with 3 replicates for each concentration, and placed in a 37 °C, 5% CO2 incubator for 1 h.

[0105] 1.3 Add 100 ng replicon RNA and 0.5 μL transfection reagent Lipfectamine ® 2000 to 50 μL opti-MEM® I medium and incubate for 15 min. Add 100 μL transfection system to each well in step 2.

[0106] 1.4 24 h after transfection of replicon RNA, cells were collected and the fluorescence value of each well was detected using Nano glo® (purchased from Promega) kit and 96-well microwell luminescence detector.

[0107] 1.5 Experimental results: Figure 4 As shown in the figure, in Huh7 cells, 24 h after replicon transfection, the replicon replication levels of the experimental groups with different Lipofermata concentrations were significantly decreased compared with the blank control group, indicating that different concentrations of Lipofermata have obvious inhibitory effects on SARS-CoV-2 virus replicons, and Lipofermata has a good inhibitory effect on SARS-CoV-2 virus at lower concentrations, and has a higher efficacy.

[0108] 2. Inhibitory effect of different concentrations of Lipofermata on MHV-A59-ZsGreen live virus in L2 and 17CL-1 cells

[0109] 2.1 L2 and 17CL-1 cells were cultured at 2×10 5 The cells were seeded at a density of 100 cells / mL in a 12-well plate, 1 mL per well, and cultured in a 37°C, 5% CO2 incubator using 10% FBS DMEM medium.

[0110] 2.2 After 24 h of culture, cell growth entered the exponential phase. Lipofermata concentration gradient groups were prepared, and 6 concentration gradients were set in L2 cells, namely 0.5 μM, 1 μM, 1.5 μM, 2 μM and 4 μM; 5 concentration gradients were set in 17CL-1 cells, namely 0.5 μM, 1 μM, 1.5 μM and 2 μM. Drugs of various concentrations were added to the cell culture wells and cultured in an incubator at 37 °C and 5% CO2 for 1 h.

[0111] 2.3 Discard the culture medium in each well, add 1 mL of 10% FBS DMEM culture medium and 10 μL of MHV-A59-ZsGreen live virus solution. Place the culture plate in a 37°C, 5% CO2 incubator. After 1 hour of incubation, discard the virus-containing culture medium, add 10% FBS DMEM culture medium containing DMSO, 0.5 μM, 1 μM, 1.5 μM, 2 μM and 4 μM Lipofermata to L2 cells, and add 10% FBS DMEM culture medium containing DMSO, 0.5 μM, 1 μM, 1.5 μM and 2 μM Lipofermata to 17CL-1 cells. Place in a 37°C, 5% CO2 incubator for 24 hours.

[0112] 2.4 Experimental results: Figure 5 As shown, in L2 and 17CL-1 cells, Lipofermata can achieve a significant inhibitory effect on MHV at lower concentrations, and is dose-dependent within a certain concentration range.

[0113] All documents mentioned in this application are cited as references in this application, just as each document is cited as reference separately. Unless they conflict with the application purpose and / or technical solution of this application, the cited documents involved in this application are cited with all contents and all purposes. When the cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the cited documents are involved in this application, the examples and preferred methods of the cited relevant technical features can also be incorporated into this application as references, but are limited to the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.

[0114] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0115] The above-described embodiments only express several implementation methods of the present application, but they cannot be understood as limiting the scope of the patent application. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present application, several variations and improvements can also be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solutions provided in the present application through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the attached claims, and the description can be used to interpret the content of the claims.

Claims

1. Use of a compound represented by formula (I) in the preparation of a drug for preventing and / or treating coronavirus infection; Formula (I).

2. The use according to claim 1, characterized in that: The coronavirus is selected from beta coronavirus.

3. The use according to claim 2, characterized in that: The coronavirus includes at least one of SARS-CoV, MERS-CoV, SARS-CoV-2 and MHV-A59.

4. Use of a pharmaceutical composition in the preparation of a drug for preventing and / or treating coronavirus infection, characterized in that: The pharmaceutical composition comprises an active ingredient and a pharmaceutically acceptable carrier; The active ingredient includes a compound represented by formula (I); Formula (I).

5. The use according to claim 4, characterized in that: The coronavirus is selected from beta coronavirus.

6. The use according to claim 5, characterized in that: The coronavirus includes at least one of SARS-CoV, MERS-CoV, SARS-CoV-2 and MHV-A59.

7. The use according to any one of claims 4 to 6, characterized in that: The pharmaceutical composition and pharmaceutically acceptable excipients are prepared into a preparation.

8. The use according to any one of claims 4 to 6, characterized in that: The dosage form of the preparation includes solid preparation, semisolid preparation and liquid preparation.

9. The use according to any one of claims 4 to 6, characterized in that: The compound represented by formula (I) is the only active ingredient in the pharmaceutical composition.

10. The use according to any one of claims 1 to 6, characterized in that: The prevention and / or treatment of coronavirus infection includes inhibiting the replication of the coronavirus in cells.